Federal Drug Sentencing: Relevant Conduct and Drug Quantity

Drug quantity can be one of the most important disputes at sentencing in a federal drug case.

A defendant may plead guilty to or be convicted of an offense involving a particular amount of drugs, only to face a substantially larger quantity in the Presentence Investigation Report.

That happens because the Federal Sentencing Guidelines generally consider relevant conduct, not simply the conduct specifically identified in the count of conviction.

But relevant conduct has limits.

In a drug conspiracy, a defendant is not automatically responsible at sentencing for every drug handled by every member of the conspiracy.

Relevant Conduct Under U.S.S.G. § 1B1.3

The starting point is U.S.S.G. § 1B1.3.

Relevant conduct can include conduct beyond the particular transaction resulting in conviction.

In federal drug cases, this can include drug transactions that were not separately charged if they qualify as relevant conduct under the Guidelines.

For certain offenses, including drug trafficking offenses sentenced under §2D1.1, relevant conduct can include acts that were part of the same course of conduct or common scheme or plan as the offense of conviction.

This is why the drug quantity used at sentencing may be greater than the amount actually seized from the defendant.

But the government must still establish that the additional drugs constitute the defendant’s relevant conduct.

Jointly Undertaken Criminal Activity Has Important Limits

A separate relevant conduct rule applies when the government seeks to hold a defendant responsible for conduct committed by others.

Under §1B1.3(a)(1)(B), a defendant involved in jointly undertaken criminal activity can be held responsible for certain acts of others.

The conduct must satisfy three requirements.

It must be:

Within the scope of the criminal activity, the defendant agreed to jointly undertake

In furtherance of that jointly undertaken criminal activity

Reasonably foreseeable in connection with that criminal activity

All three requirements matter.

Scope Comes Before Foreseeability

One of the most important principles in relevant conduct law is the distinction between scope and foreseeability.

The question is not simply whether another person’s drug activity was reasonably foreseeable to the defendant.

The court must first determine the scope of the criminal activity that the particular defendant agreed to jointly undertake.

Only conduct falling within that scope can potentially be attributed to the defendant under §1B1.3(a)(1)(B).

This means that conduct can be completely foreseeable to a defendant and still fall outside the defendant’s relevant conduct.

Knowledge is not the same thing as agreement.

Relevant Conduct Rules in the 11th Circuit

The Eleventh Circuit addressed this issue in United States v. Barry, 163 F.4th 1346 (11th Cir. 2026)

In determining whether a defendant should be held responsible for the quantities of drugs handled by other participants, the sentencing court must examine the defendant’s individual role in the criminal activity.

The Eleventh Circuit explained that the court must determine the scope of the criminal activity undertaken by the particular defendant before determining the drug quantities reasonably foreseeable in connection with that activity.

This individualized inquiry is critical.

A defendant’s membership in a drug conspiracy does not necessarily establish that the defendant agreed to participate in every transaction undertaken by every other conspirator.

The Scope of Relevant Conduct Is Not Necessarily the Scope of the Conspiracy

The Sentencing Guidelines expressly distinguish between criminal liability for conspiracy and relevant conduct at sentencing.

The scope of the jointly undertaken criminal activity for purposes of §1B1.3 is not necessarily the same as the scope of the entire conspiracy.

That distinction can have enormous consequences.

A defendant might be legally guilty of participating in a broad conspiracy while having agreed to undertake only a limited portion of the criminal activity.

Relevant conduct focuses on the scope of the activity the individual defendant agreed to undertake, not merely the size of the conspiracy charged in the indictment.

A Drug Defendant Is Not Automatically Responsible for the Entire Conspiracy

Consider a defendant who agrees to distribute a limited quantity of cocaine for a large drug organization.

The defendant knows the supplier deals in much larger quantities and has numerous other customers.

That knowledge alone does not necessarily make all of the supplier’s drug transactions relevant conduct attributable to the defendant.

The sentencing court must determine what criminal activity the defendant actually agreed to undertake.

If the defendant’s agreement was limited, the defendant’s relevant conduct may also be limited even though the defendant knew that the larger organization was distributing substantially greater quantities.

Reasonable Foreseeability Alone Is Not Enough

This distinction is frequently overlooked.

The government may argue that a large quantity of drugs should be attributed to a defendant because the defendant could reasonably foresee that the organization was handling those drugs.

But foreseeability is only part of the analysis.

The proper sequence is:

First: What criminal activity did this defendant agree to jointly undertake?

Second: Was the other person’s conduct in furtherance of that activity?

Third: Was that conduct reasonably foreseeable in connection with the jointly undertaken activity?

The government should not be permitted to skip the first question and proceed directly to foreseeability.

Individualized Findings Matter

The Eleventh Circuit has repeatedly emphasized the importance of examining the particular defendant’s role when determining responsibility for drug quantities handled by others.

That inquiry can include evidence of explicit agreements as well as agreements fairly inferred from the conduct of the defendant and other participants.

The relevant question is not merely what the conspiracy as a whole accomplished.

The court should determine the scope of the criminal activity the individual defendant agreed to undertake and then determine what additional conduct properly falls within that scope.

The Government Must Prove Disputed Drug Quantity

The government generally bears the burden of establishing sentencing facts used to increase the Guidelines calculation by a preponderance of the evidence.

This becomes particularly important when the defense makes a specific objection to drug quantities contained in the Presentence Investigation Report.

A defendant should not simply state that he disagrees with the PSR.

The objection should identify the particular factual allegation being disputed and explain the basis for the objection.

Once a material sentencing fact is properly disputed, the government must establish the factual basis necessary to support its requested Guidelines calculation.

A PSR Is Not Evidence Merely Because It Says Something Happened

Presentence Investigation Reports often contain information obtained from investigative reports, cooperating defendants, confidential informants, and government agents.

Some of that information may be reliable.

Some may not be.

When a disputed drug quantity materially increases the Guidelines range, the defense should examine the actual source supporting the allegation.

Questions may include:

Who supplied the information?

Was the information given under oath?

Has the witness given inconsistent accounts?

Is there independent corroboration?

Does the witness have an incentive to exaggerate the defendant’s involvement?

Are the alleged quantities based on actual transactions or estimates?

Does the information concern conduct within the scope of the defendant’s jointly undertaken criminal activity?

The sentencing court’s factual findings must have an adequate evidentiary basis.

Cooperating Witness Testimony Can Determine Drug Quantity

Many federal drug cases depend heavily on cooperating witnesses.

A cooperating witness may estimate that the defendant purchased or distributed a particular amount of drugs each week for months or years.

Those estimates can produce enormous quantities when multiplied over time.

The defense should carefully examine the foundation for such testimony.

For example, did the witness personally participate in every alleged transaction?

Can the witness actually remember the frequency and amount?

Are there telephone records, financial records, surveillance reports or intercepted communications supporting the estimate?

Has the witness changed his account after entering a cooperation agreement?

A sentencing court may rely on credible testimony, but drug quantity cannot properly rest on pure speculation.

Estimating Drug Quantity

The government does not necessarily have to seize every gram of drugs attributed to a defendant.

When the amount seized does not reflect the scale of the offense, the Guidelines permit the court to approximate drug quantity.

That does not mean the court may guess.

An approximation must have an adequate evidentiary foundation.

For example, evidence regarding the amounts involved in typical transactions and their frequency may sometimes provide a basis for estimating quantity.

But small assumptions can become extremely significant when extrapolated across months or years.

The defense should therefore examine both components of an estimate:

How much was supposedly involved in each transaction?

and

How often did those transactions actually occur?

An unsupported assumption in either component can substantially inflate the resulting drug quantity.

Same Course of Conduct or Common Scheme or Plan

Relevant conduct can also involve the defendant’s own uncharged drug activity.

Under §1B1.3(a)(2), certain offenses may be considered when they were part of the same course of conduct or common scheme or plan as the offense of conviction.

That analysis is different from attributing another person’s conduct under the jointly undertaken criminal activity rule.

The government must establish the connection between the additional conduct and the offense of conviction required by the Guidelines.

A prior drug transaction does not automatically become relevant conduct merely because it involved the same controlled substance.

The relationship between the events must be examined under the applicable Guidelines standard.

Drug Quantity Under U.S.S.G. § 2D1.1

Once the court determines the drug quantity properly attributable to the defendant, U.S.S.G. §2D1.1 generally uses that quantity to determine the base offense level in a federal drug trafficking case.

That calculation can dramatically affect the advisory Guidelines range.

For this reason, relevant conduct disputes are not technical sentencing arguments.

A successful objection to drug quantity can reduce the offense level and substantially change the advisory sentencing range.

Drug Quantity Can Also Affect Statutory Penalties

The Sentencing Guidelines are not the only consideration.

Drug type and quantity can also affect statutory penalties under 21 U.S.C. §841(b).

The constitutional and statutory rules governing the quantities necessary to trigger enhanced statutory penalties are distinct from the Guidelines relevant conduct rules used to calculate an advisory sentencing range.

A careful sentencing analysis should therefore distinguish between:

The quantity supporting the statutory penalty

and

The quantity is properly considered as relevant conduct under the Sentencing Guidelines.

They are not necessarily the same.

Objecting to Drug Quantity at Sentencing

A drug quantity objection should be specific.

Rather than simply stating that the defendant disputes the government’s calculation, the defense should identify the transactions, witnesses, dates, quantities or assumptions being challenged.

The defense should also distinguish among different legal objections.

For example:

The alleged transaction never occurred.

The witness’s quantity estimate is unreliable.

The government has not established the frequency of the alleged transactions.

The conduct was outside the scope of the defendant’s jointly undertaken criminal activity.

The conduct was not in furtherance of that activity.

The conduct was not reasonably foreseeable.

The defendant’s own uncharged conduct was not part of the same course of conduct or common scheme or plan.

Separating these issues can make the sentencing objection considerably more precise.

Relevant Conduct Can Be One of the Most Important Sentencing Issues

Federal drug sentencing frequently involves conduct extending well beyond the drugs physically seized from the defendant.

But the term relevant conduct does not mean that every drug connected in some way to a conspiracy automatically belongs in the defendant’s Guidelines calculation.

The government must establish the factual and legal basis for attributing the additional quantity to the individual defendant.

For jointly undertaken activity, the critical starting point is the scope of what the defendant actually agreed to undertake.

Scope first. Foreseeability second.

Contact Federal Drug Sentencing Attorney Michael J. Petro

Drug quantity can dramatically change a defendant’s advisory Federal Sentencing Guidelines range.

A Presentence Investigation Report that attributes drugs handled by other people to a defendant should be carefully examined to determine whether those quantities actually qualify as relevant conduct under U.S.S.G. §1B1.3.

Michael J. Petro represents defendants in federal criminal cases involving drug sentencing, relevant conduct and disputed Guidelines calculations.

Facing federal sentencing where disputed drug quantities increase your Guidelines? Call federal criminal defense attorney Michael J. Petro to discuss the drug quantity and relevant conduct calculation in your case.